Ranbaxy Labs hit a new 52-week low today at Rs.333.10 and though it has recovered from this low, it remains deeply in the red, down almost 4%.

The company has suffered a serious blow post the US FDA findings and though the company has tried to salvage its image by trying to convey through the media that its moved ahead and things are now behind it, another news came in – its Mohali unit has come under the US FDA radar as it has found some deviations from its norms there. This is the third unit, after Paonta Sahib and Dewas to come under the scanner.